Following Actavis’ acquisition of Allergan, anticipated in 2Q15, Brent Saunders will continue to lead the global company as chief executive officer and president and a member of the board of directors. Paul Bisaro will remain executive chairman of the board. Mr. Saunders will lead an expanded senior management team comprised of leaders from both Actavis and Allergan. 

“We are committed to realizing the full potential of the historic combination of Actavis and Allergan beginning on Day 1, and announcing the proposed leadership of the combined company is a critical step in achieving that objective,” said Mr. Saunders.  “The management structure we are announcing today will ensure that we capitalize on the value of Allergan’s world-renowned businesses and the proven track record of the leaders of its powerful and critically important franchises. I am particularly pleased to announce that following the close Douglas Ingram, president, Allergan, will continue as a special advisor to me. The combined company will benefit from Doug’s experience and expertise as we unite the two businesses, and help us ensure that we integrate the two companies while recognizing and capitalizing on Allergan’s unique product portfolio and market leadership positions. In this structure we demonstrate our commitment to combine the ‘best of the best’ talent from both organizations.

“At close, this combined leadership will ensure that the new company capitalizes on our expanded global commercial footprint, maintains our continued dominance as a world leader in generics and that we elevate our commitment to brand innovation and development by making brand R&D directly report to the CEO level.